Coronavirus disease 2019 (COVID-19)-associated hypercoagulability and platelet
hyperactivity are characteristic of COVID-19 infection and contribute to an increased …

OBJECTIVE: The purpose of the present study is to see if the presence of angiotensin-
converting enzyme 2 (ACE-2), transmembrane serine protease 2 (TMPRSS), and P-selectin …

Introduction Thromboinflammatory complications are well described sequalae of
Coronavirus Disease 2019 (COVID-19), and there is evidence of both hyperreactive platelet …

Higher thrombotic burden in the acute phase of COVID-19 relies on a complex interplay
between pro-inflammatory cytokine/chemokine release, increased endothelial …

OBJECTIVE: There is more pronounced hypercoagulation in COVID-19 infection than in
other viral lung infections. Oxidized phospholipids (OxPLs) appear in COVID-19-infected …

Dear Editors-in-Chief Lillicrap and Morrissey, We have read with great attention the article
“Coagulopathy in COVID-19” written by Toshiaki Iba et al, published in the September issue …

Platelets may be a target of bacteria and viruses, which can directly or indirectly activate
them so promoting thrombosis. In accordance with this, community-acquired pneumonia …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread all over the world
immediately after the first patient infected with this virus was discovered in Wuhan, China, in …

Patients with COVID-19 often have hypoxemia, impaired lung function, and abnormal
imaging manifestations in acute and convalescent stages. Alveolar inflammation, pulmonary …

The SARS-CoV-2 virus, causing the devastating COVID-19 pandemic, has been reported to
affect platelets and cause increased thrombotic events, hinting at the possible bidirectional …